Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 11/20 | 0.47 |
| ▸ | PDE1A | P54750 | 4/20 | 0.44 |
| ▸ | PDE1B | Q01064 | 4/20 | 0.44 |
| ▸ | PDE1C | Q14123 | 4/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8239311 | 0.96 | PDE5A (0.50) | PDE5APDE1APDE1BPDE1CTSHR | |
| SCHEMBL13316921 | 0.83 | PDE5A (0.48) | PDE5APDE1APDE1BPDE1CTSHR | |
| SCHEMBL8246208 | 0.82 | PDE5A (0.48) | PDE5APDE1APDE1BPDE1CTSHR | |
| SCHEMBL13316917 | 0.81 | PDE5A (0.46) | PDE5APDE1APDE1BPDE1CTSHR | |
| SCHEMBL13316922 | 0.80 | PDE5A (0.52) | PDE5APDE1APDE1BPDE1CHDAC3 | |
| SCHEMBL5603367 | 0.79 | PDE5A (0.58) | PDE5APDE1APDE1BPDE1CPOLB | |
| SCHEMBL13316920 | 0.79 | PDE5A (0.52) | PDE5APDE1APDE1BPDE1CTSHR | |
| SCHEMBL13316919 | 0.78 | PDE5A (0.48) | PDE5APDE1APDE1BPDE1CTSHR | |
| SCHEMBL13316916 | 0.78 | PDE5A (0.49) | PDE5APDE1APDE1BPDE1CTSHR | |
| SCHEMBL8248231 | 0.77 | PDE5A (0.53) | PDE5APDE1APDE1BPDE1CHDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152188-A1 | Novel Heterocyclic Compounds | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2010-06-17 | — | — | US | disclosed |
| US-20100152188-A1 | Novel Heterocyclic Compounds | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2010-06-17 | — | — | US | disclosed |
| WO-2007017728-A2 | NOVEL HETEROCYCLIC COMPOUNDS | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152188-A1 | Novel Heterocyclic Compounds | CYP11B2, CYP3A5, CYP11B1 | PDE5A 258/4885PDE1A 3451/4885PDE1B 2853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.